Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies

NCT05294731 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT05294731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05294731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies
Lead sponsor
BeiGene
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 6, 2022
Completion date
January 31, 2029
Enrollment
146 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell malignancy, chronic lymphocytic leukemia/small lymphocytic lymphoma, dlbcl unclassifiable, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, non-hodgkin lymphoma, richter's transformation, waldenström macroglobulinemia